Literature DB >> 11242597

Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders.

J T Prchal1.   

Abstract

The absolute polycythemias--those with increased red blood cell mass--can be divided into two groups: primary, caused by acquired or inherited mutations leading to a "gain-of-function" abnormalities expressed within the erythroid progenitors; and secondary, due to circulating serum factors, typically erythropoietin, stimulating erythropoiesis. This overview concentrates on the molecular biology of polycythemia vera (PV) discussed in the context of other polycythemic disorders. Recent advances in the regulation of erythropoiesis, as they may relate to polycythemic states, are discussed as a background for those well-defined polycythemic states wherein the molecular defect has not yet been elucidated. A number of cellular abnormalities associated with PV, including the hyperresponsiveness of PV progenitors to many cytokines as well as decreased expression of the thrombopoietin receptor on platelets and increased expression of Bcl-xL, suggest that the PV defect alters a number of cellular functions and is not restricted to cytokine receptor signal transduction. The increasing number of recognized instances of familial incidence of PV suggests that in these families the predisposition for PV is inherited as a dominant trait, and that PV is acquired as a new mutation that leads to a clonal hematopoiesis and may be due to loss of heterozygosity. The existence of these families provides a unique opportunity for isolation of the mutations in the gene leading to PV. Semin Hemaol 38(suppl 2):10-20. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11242597     DOI: 10.1016/s0037-1963(01)90135-0

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  7 in total

Review 1.  JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David P Steensma
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

2.  Polycythemia as the first manifestation of Cushing's disease.

Authors:  A Gursoy; A Dogruk Unal; S Ayturk; S Karakus; A Nur Izol; N Bascil Tutuncu; N Guvener Demirag
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

3.  Correction of murine β-thalassemia after minimal lentiviral gene transfer and homeostatic in vivo erythroid expansion.

Authors:  Olivier Negre; Floriane Fusil; Charlotte Colomb; Shoshannah Roth; Beatrix Gillet-Legrand; Annie Henri; Yves Beuzard; Frederic Bushman; Philippe Leboulch; Emmanuel Payen
Journal:  Blood       Date:  2011-03-24       Impact factor: 22.113

Review 4.  Advances in understanding the pathogenesis of primary familial and congenital polycythaemia.

Authors:  Lily J Huang; Yu-Min Shen; Gamze B Bulut
Journal:  Br J Haematol       Date:  2010-01-20       Impact factor: 6.998

Review 5.  Back to biology: new insights on inheritance in myeloproliferative disorders.

Authors:  Evan M Braunstein; Alison R Moliterno
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

6.  Computational analysis of prolyl hydroxylase domain-containing protein 2 (PHD2) mutations promoting polycythemia insurgence in humans.

Authors:  Giovanni Minervini; Federica Quaglia; Silvio C E Tosatto
Journal:  Sci Rep       Date:  2016-01-12       Impact factor: 4.379

7.  Effects of idiopathic erythrocytosis on the left ventricular diastolic functions and the spectrum of genetic mutations: A case control study.

Authors:  Alpay Yesilaltay; Hasan Degirmenci; Turker Bilgen; Duygu Yasar Sirin; Duygu Bayir; Pelin Degirmenci; Atakan Tekinalp; Seref Alpsoy; Yildiz Okuturlar; Burhan Turgut
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.